Skip to main content

Table 1 Spearman's correlations on changes in the 2 clinical trials

From: Final validation of a new composite disease activity score for juvenile idiopathic arthritis: the Juvenile Arthritis Disease Activity Score (JADAS)

 

Methotrexate trial

Meloxicam trial

 

JADAS-71

JADAS-27

JADAS-10

JADAS-71

JADAS-27

JADAS-10

CHAQ

0.46

0.50

0.51

0.44

0.43

0.45

DAS28

0.78

0.80

0.79

0.74

0.74

0.70

CDAI

0.88

0.86

0.72

0.87

0.86

0.75

  1. The JADAS-10 revealed the best discriminative validity, followed by the JADAS-27 and the JADAS-71.
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096